Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus. Methods: Hepatitis B e antigen (HBeAg)-positive, highly viremic pregnant women were recruited for this prospective study. Treatment with LdT was started from 28 weeks of gestation. Virological and biochemical markers were examined before LdT treatment, antepartum and postpartum. Serial blood samples at the same time were collected to detect cytokines and cortisol (COR). Results: Fifty-six of 153 patients (36.6%) had postpartum hepatic flares, defined as a 2-fold increase in alanine aminotransferase 6 weeks after delivery. Age and the antepartum alanine aminotransferase and postpartum HBeAg levels were independent influencing factors of postpartum hepatic flares. Cytokines showed no regularity during or after pregnancy. Compared with the patients with no postpartum flares, the patients with flares had lower baseline interferon γ and COR levels (p=0.022 and p=0.028) and higher postpartum interferon γ levels (p=0.026). Conclusions: A high proportion of highly viremic and immune-tolerant pregnant patients treated with LdT in the last trimester had postpartum hepatic flares, which implied that these patients entered the immune clearance phase after delivery. Thus, this may create an appropriate opportunity for re-antiviral therapy.
Abstract
Background/Aims: To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus. Methods: Hepatitis B e antigen (HBeAg)-positive, highly viremic pregnant women were recruited for this prospective study. Treatment with LdT was started from 28 weeks of gestation. Virological and biochemical markers were examined before LdT treatment, antepartum and postpartum. Serial blood samples at the same time were collected to detect cytokines and cortisol (COR). Results: Fifty-six of 153 patients (36.6%) had postpartum hepatic flares, defined as a 2-fold increase in alanine aminotransferase 6 weeks after delivery. Age and the antepartum alanine aminotransferase and postpartum HBeAg levels were independent influencing factors of postpartum hepatic flares. Cytokines showed no regularity during or after pregnancy. Compared with the patients with no postpartum flares, the patients with flares had lower baseline interferon γ and COR levels (p=0.022 and p=0.028) and higher postpartum interferon γ levels (p=0.026). Conclusions: A high proportion of highly viremic and immune-tolerant pregnant patients treated with LdT in the last trimester had postpartum hepatic flares, which implied that these patients entered the immune clearance phase after delivery. Thus, this may create an appropriate opportunity for re-antiviral therapy.
참고문헌 (29)
- Cui F, "Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation", Vaccine, 31(Suppl 9), pp.J36~J42 (2013)
- Wiseman E, "Perinatal transmission of hepatitis B virus : an Australian experience", Med J Aust, 190, pp.489~492 (2009)
- Xu WM, "Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection : a multicentre, randomized, double-blind, placebocontrolled study", J Viral Hepat, 16, pp.94~103 (2009)
- Zou H, "Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers", J Viral Hepat, 19, pp.e18~ (2012)
- Zhang H, "Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice", Hepatology, 60, pp.468~476 (2014)
- Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
- ter Borg MJ, "Exacerbation of chronic hepatitis B infection after delivery", J Viral Hepat, 15, pp.37~41 (2008)
- Tan HH, "Chronic hepatitis B virus(HBV)infection in pregnancy", Hepatol Int, 2, pp.370~375 (2008)
- Lin HH, "Hepatitis B postpartum e antigen clearance in hepatitis B carrier mothers : correlation with viral characteristics", J Gastroenterol Hepatol, 21, pp.605~609 (2006)
- Rehermann B, "Pathogenesis of chronic viral hepatitis : differential roles of T cells and NK cells", Nat Med, 19, pp.859~868 (2013)
- Trowsdale J, "Mother’s little helpers : mechanisms of maternal-fetal tolerance", Nat Immunol, 7, pp.241~246 (2006)
- Chinese Society of Hepatology, "The guideline of prevention and treatment for chronic hepatitis B : a 2015 update", Zhonghua Gan Zang Bing Za Zhi, 23, pp.888~905 (2015)
- European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Lu J, "Effect of peg-interferon α-2a combined with adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA", Liver Int, 35, pp.1692~1699 (2015)
- Giles M, "Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B", Gut, 64, pp.1810~1815 (2015)
- Wegmann TG, "Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?", Immunol Today, 14, pp.353~356 (1993)
- Xu C, "A critical role for murine complement regulator crry in fetomaternal tolerance", Science, 287, pp.498~501 (2000)
- Aluvihare VR, "Regulatory T cells mediate maternal tolerance to the fetus", Nat Immunol, 5, pp.266~271 (2004)
- Faas MM, "Uterine NK cells and macrophages in pregnancy", Placenta, 56, pp.44~52 (2017)
- Kramvis A, "Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of hepatitis B virus", Front Microbiol, 9, pp.2521~ (2018)
- Lin HH, "Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers", J Med Virol, 29, pp.1~6 (1989)
- Saito S, "Th1", Th2, Am J Reprod Immunol, pp.2010, 63[DOI]
- Mor G, "The unique immunological and microbial aspects of pregnancy", Nat Rev Immunol, 17, pp.469~482 (2017)
- Wang GQ, "Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients", J Viral Hepat, 20(Suppl 1), pp.9~17 (2013)
- Swain SL, "Expanding roles for CD4+T cells in immunity to viruses", Nat Rev Immunol, 12, pp.136~148 (2012)
- Wu ZG, "Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis", J Viral Hepat, 17(Suppl 1), pp.24~33 (2010)
- Park JJ, "Hepatitis B virus : specific and global T-cell dysfunction in chronic hepatitis B", Gastroenterology, 150, pp.684~695 (2016)
- Ma XJ, "Study on the distribution of CD8+ memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection", Eur Rev Med Pharmacol Sci, 21, pp.4675~4679 (2017)